Among the patients hospitalized for COVID-19, the use of Qingfei Paidu Tang was associated with halving the risk of mortality, without raising the risk of acute liver injury or acute kidney injury.
Of the 8939 patients included, 28.7% received QPT. The COVID-19 related mortality was 1.2% among the patients receiving QPT and 4.8% among those not receiving QPT. After adjustment for patient characteristics and concomitant treatments, QPT use was associated with a relative reduction of 50% in-hospital COVID-19 related mortality. This association was consistent across subgroups by sex and age.
Meanwhile, the incidences of acute liver injury and acute kidney injury were comparable between patients receiving QPT and those not receiving QPT. The major study limitations included that the study was an observational study based on real-world data rather than a randomized control trial, and the quality of data could be affected by the accuracy and completeness of medical records.
In this analysis based on a national registry of hospitalized patients with COVID-19, we first demonstrated that QPT use was associated with halving the risk of in-hospital mortality, without any significant increase in the risk of adverse effects, such as acute liver injury or acute kidney injury. Our findings have provided new evidence and insights regarding the treatment of COVID-19.
